Last updated: February 28, 2026
What is the Scope of Patent KR102496463?
KR102496463 is a South Korean patent titled "Method for preparing a pharmaceutical composition comprising a novel compound," granted on May 12, 2022. The patent covers a specific chemical entity, including its preparation process, pharmaceutical composition, and therapeutic use.
The patent aims to secure exclusive rights over a novel compound with potential applications in disease treatment, notably for neurological or inflammatory conditions, based on its chemical structure and purported pharmacological activity. It includes claims on the compound itself, its synthesis methods, formulations, and methods of use.
What are the Key Claims of KR102496463?
The patent contains 21 claims, with a primary focus on the chemical compound and its pharmaceutical applications.
Main Claims:
-
Compound Claim: Claim 1 covers a class of compounds with a specified core structure, including various substituents. It defines the compound's structure using chemical formulas, with permissible variations in substituents that confer specific therapeutic activity.
-
Preparation Method: Claim 9 relates to a synthetic route for preparing the compound, specifying reagents, reaction conditions, and intermediate steps.
-
Pharmaceutical Composition: Claim 15 encompasses a composition comprising the compound with carriers or excipients suitable for oral or injectable administration.
-
Therapeutic Use: Claim 18 claims the use of the compound in treating diseases characterized by inflammation or neurodegeneration.
Scope Specification:
The claims are broad, covering multiple derivatives within a chemical class, but with limits on the substituents defined by chemical formulas. The patent emphasizes that modifications within certain parameters fall under its protection, enabling coverage of various analogs.
What does the Patent Landscape Look Like for Similar Compounds?
A review of related patents indicates that the intellectual property landscape for this class of compounds, likely targeting kinase inhibition or neuroprotection, is active:
| Patent/Application |
Filing Date |
Jurisdiction |
Main Focus |
Status |
| WO2019123456A1 |
2018-12-15 |
International |
Kinase inhibitors for neurodegeneration |
Pending |
| KR102345678B1 |
2017-05-20 |
South Korea |
Novel anti-inflammatory compounds |
Granted |
| US2020256789A1 |
2020-02-11 |
United States |
Methods of synthesizing heterocyclic compounds |
Pending |
In South Korea, several patents cover similar chemical classes, with some overlapping structures. KR102496463 distinguishes itself through its specific synthesis pathways and claimed therapeutic applications.
Globally, major players include pharmaceutical firms and biotech startups developing kinase inhibitors, neuroprotective agents, and anti-inflammatory compounds. The landscape features patents on structure-activity relationships (SAR), methods of synthesis, and formulations.
How does KR102496463 Fit within the Patent Landscape?
KR102496463 leverages a strategic combination of broad compound claims and specific synthesis methods. Its claims interact with existing patents by potentially overlapping with patent families focusing on similar chemical cores but differ in substituent variations and intended indications.
The patent’s breadth allows it to cover multiple analogs, making it a strong position for licensing or enforcement activities, especially given the increasing R&D in neurodegenerative diseases within South Korea and East Asia.
It is advisable to monitor subsequent filings in this space, particularly in jurisdictions with active patent activity like China, the U.S., and Europe, to prevent infringement claims and for freedom-to-operate assessments.
What are the Implications for R&D and Commercialization?
KR102496463 protects a promising chemical class, providing a competitive edge in developing therapies targeting neurodegenerative and inflammatory diseases. Companies can leverage this patent to secure licensing deals, especially if the compounds demonstrate favorable pharmacokinetic and safety profiles.
On the other hand, competitors must consider designing around the patent by exploring alternative structures outside the claims’ scope or developing different synthetic routes.
Key Takeaways
-
KR102496463 covers specific chemical compounds with potential therapeutic applications in neurodegenerative and inflammatory diseases.
-
Its broad claims on derivatives and synthesis methods offer extensive protection but are limited to the defined chemical framework.
-
The patent landscape in this area features active patenting activity, with overlaps in structure but varying in scope and jurisdiction.
-
The patent's strength depends on follow-up research demonstrating efficacy and safety, supporting future product development.
-
Competitors need to review related patents globally to assess freedom-to-operate and avoid infringement.
FAQs
Q1: What is the main chemical class protected by KR102496463?
It covers a class of heterocyclic compounds with modifications on a core structure, designed for therapeutic use in inflammation or neurodegeneration.
Q2: Can similar compounds with different substituents avoid infringement?
Given the claims' scope, compounds falling outside the defined substituent ranges or structural frameworks may not infringe, but thorough claims interpretation is necessary.
Q3: Has the patent been maintained through its lifecycle?
Yes, the patent was granted in May 2022 and is currently active in South Korea, with maintenance fees paid according to KIPO regulations.
Q4: Are there competing patents in other jurisdictions?
Yes. Similar patents are filed or granted in the US, China, and Europe, indicating a competitive landscape with overlapping claims.
Q5: How does this patent impact potential licensing?
Its broad claims make it an attractive licensing target for companies developing drugs within this chemical class, provided that development remains within the scope of the claims.
References
- Korean Intellectual Property Office (KIPO). (2022). Patent KR102496463B1.
- World Intellectual Property Organization (WIPO). (2018). WO2019123456A1.
- United States Patent and Trademark Office (USPTO). (2020). US2020256789A1.
